CeeTox Services
CeeTox, Inc. provides a unique and robust in vitro toxicity screening approach designed to improve the discovery process and support the pharmaceutical, chemical, cosmetic, and biotech industries globally. Our signature CTOX Panel uses a proprietary algorithm that incorporates multiple-endpoint analysis, dose-response profiles, Pgp interaction, solubility, metabolic stability, and in vivo validation to provide an estimate of the sustained blood concentration where toxicity would first be expected to occur in a rat 14-day repeat dose study.
We improve the efficiency of early discovery research with data that allows teams to optimize safety by identifying liabilities associated with new chemical entities (NCEs) and make better decisions earlier. The result is reduced development time and selection of candidates with a higher probability of success in preclinical animal testing. CeeTox helps you make better decisions earlier in discovery to bring safer products to market sooner.
- We provide a HTS (high throughput screening) that rank-orders large numbers of “hits” based on toxicity;
- We analyze the results of 10 different biochemical assays to predict the point at which toxicity will first occur in vivo and gain detailed information on the mechanisms and sub-cellular sites of toxicity;
- We provide in vitro assays to evaluate CYP enzyme induction, metabolic activation, and CYP inhibition to evaluate the drug-drug interaction potential of a compound;
- We evaluate tissue-specific toxicity, including heart, liver, and kidney, and we assess anti-tumor drug candidates;
- We assess endocrine disruption, including estrogen responsive (ER) transactivation and androgen responsive (AR) transactivation and human estrogen receptor binding (alpha and beta) and human androgen receptor binding.
Please view details of some our toxicity screening and ADME services on our website, or download our full list of toxicity screening services and our full list of ADME services